Abstract
Objective: Risk-reducing salpingo-oophorectomy (RRSO) is standard management for women with BRCA1/2 mutations; however, the role of concurrent hysterectomy (CH) remains controversial. Shu et al. published the largest study addressing endometrial cancer among BRCA carriers in 2016, suggesting an increased risk of serous uterine cancer in women with BRCA1 mutations. Currently, there is no official recommendation for CH with RRSO; however, many practitioners offer this combined procedure. We sought to review our institutional experience with RRSO and CH.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
